Any content you receive is for information purposes only. Always conduct your own research. *Disseminated on behalf of Optimi Health Corp.
Optimi Health Corp. (NASDAQ: OPTH) Just Hit Jeff Ackerman’s Watchlist This Morning—Monday, June 8, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Get (OPTH) On The Radar While It’s Still Early…
June 8, 2026 Following a Recent Uplisting (Nasdaq: OPTH) is Now in Our Focus Early This Morning Dear Reader, A little-known pharmaceutical manufacturer just announced its highest-purity natural Psi-locy-bin extract to date. The name is Optimi Health Corp. (NASDAQ: OPTH) — and because it only recently uplisted to the Nasdaq, this is one many readers may not have seen yet. (OPTH) is already shipping commercial product to authorized clinics in Australia while many peers remain focused on clinical development. And now, analyst coverage has arrived too — with Diamond Equity Research initiating coverage. OPTH isn't waiting for regulatory approval — it's already shipping commercial product to authorized clinics in Australia, banking real revenue while most peers are still running Phase 2 trials. Here's what's breaking at Stock News Trends that has us watching OPTH heading into this morning’s session—Monday, June 8, 2026. 
But keep in mind, OPTH less than 2.5M shares listed as available to the public right now. When companies have small floats like this, the potential exists for big moves if demand begins to shift. That combination — a fresh Nasdaq listing, active commercial shipments, new analyst coverage, and a small public float — is exactly why OPTH deserves a closer look right now. This is not a company still trying to prove it can build compliant infrastructure; Optimi already has licensed facilities, regulated production, and commercial distribution underway. So before we get into the recent potential catalysts, here’s the foundation readers need to understand first. Company Overview
Optimi Health Corp. is a Canadian GMP-certified pharmaceutical manufacturer specializing in the regulated production and international export of M-D-M-A and Psi-locy-bin for prescription-based mental health therapies. Headquartered in Vancouver, British Columbia, the company operates two purpose-built 10,000-square-foot pharmaceutical-grade facilities in Princeton, B.C., where it holds a Health Canada Dr-ug Establishment Licence (DEL), GMP certification, a Dealer's Licence, and a Class A Precursor Licence. The company's vertically integrated platform spans licensed cultivation, extraction, formulation, encapsulation, quality control, and distribution. Its installed manufacturing capacity supports approximately 1 Mln M-D-M-A capsules and 1 Mln Psi-locy-bin capsules annually, sufficient to support more than 200,000 patients per year under episodic treatment models — all without incremental capital expenditure. OPTH is one of the only companies globally with both M-D-M-A and Psi-locy-bin products actively supplied into a regulated prescription market. Its commercial revenues are currently anchored in Australia, where the Therapeutic Goods Administration (TGA) has rescheduled both compounds to Schedule 8, enabling psychiatrist-led prescribing for PTSD and treatment-resistant depression (TRD). As of Q1 2026, OPTH has shipped over 6K doses, supplying sufficient product for more than 500 patients through Australia's Authorised Prescriber Scheme. In May 2026, the company completed a $15M oversubscribed public offering alongside its Nasdaq uplisting, materially strengthening its balance sheet and extending its execution runway as commercialization scales. Mainstream Attention Is Building
Interest in ps-ych-ede-lic compounds has increasingly moved into the mainstream. Over the years, several well-known technology leaders, including Apple cofounder Steve Jobs and OpenAI CEO Sam Altman, have publicly discussed their experiences with ps-ych-ede-lic substances, while entrepreneurs such as Bryan Johnson have recently brought additional attention to the category. Elon Musk and Google cofounder Sergey Brin have also been mentioned in media coverage surrounding mi-cro-do-sing, further illustrating how visible the topic has become across technology and business circles. While these individuals have no connection to OPTH, their public comments and media attention highlight the growing visibility of ps-ych-ede-lic-related discussions across technology, healthcare, and business communities. Why OPTH Is On Our Radar
A Fast-Growing Market With Limited GMP-Certified SuppliersThe global Ps-ych-ede-lic therapeutics market is forecast to grow over 200% — from approximately $3.41B in 2026 to approximately $11.03B within the next decade. Within that, the Ps-ych-ede-lic active pharmaceutical ingredient (API) market alone is projected to reach $15–17B by the early-to-mid 2030s, implying a CAGR of 15.2%. Most of that value flows to upstream, GMP-certified manufacturers — exactly the position OPTH occupies. While peers like Compass Pathways ($1.65B market cap) and AtaiBeckley ($1.58B) remain pre-commercial, according to the Diamond Equity Research report, OPTH is already generating pharmaceutical revenues from two indications in a live reimbursed market. Commercial Traction in Australia — With Expanding Access
Australia is the world's most advanced commercial market for prescribed Psi-locy-bin and M-D-M-A. OPTH's M-D-M-A shipments have scaled from 160 doses in September 2024 to 1,000-dose repeat orders through February 2026. The company's Psi-locy-bin products entered the Australian market in August 2025 and are already included in Medibank's insurance-backed psychotherapy program — Medibank being Australia's largest private health insurer. On May 29, 2026, the TGA issued updated Authorised Prescriber recommendations that broaden therapist eligibility and accept a wider range of treatment settings, potentially expanding OPTH's addressable clinic base. On June 2, 2026, OPTH completed a commercial Psi-locy-bin production run of 5mg capsules for TRD — with additional product earmarked for planned clinical trials in the United States and Europe. Analyst Coverage and Financial Position
Diamond Equity Research initiated coverage on May 27, 2026 with a price target of C$15.00 per share — representing approximately 89% potential upside from the C$7.95 range at the time of the report. The DCF-based valuation uses a WACC of 10.91% and a 2.0% terminal growth rate, modeling Australia as the primary revenue driver. Analyst Hunter Diamond, CFA, projects long-term gross margins of approximately 75%, driven by the company's largely fixed-cost GMP infrastructure and protocol-defined dosing. Following its oversubscribed $15M Nasdaq uplisting, OPTH's balance sheet has been materially strengthened. Prior to the offering, the company held a cash balance of approximately C$491.75K (as of December 2025). Management estimates EBITDA breakeven at approximately 1,000 patients per month — with current utilization well below 1% of installed capacity. 7 Reasons Why OPTH is Topping Our Watchlist This Morning —Monday, June 8, 2026…
1. Fresh Nasdaq: After recently joining the Nasdaq, OPTH may still be unfamiliar to many U.S. market participants who have not yet followed the story. 2. Small Float: With fewer than 2.5M shares listed as available to the public, OPTH’s small float could witness the potential for big moves if demand begins to shift. 3. New Coverage: Diamond Equity Research recently initiated coverage on OPTH, bringing additional visibility to the company and its business model. 4. Commercial Shipments: Unlike many companies in the sector that remain focused on clinical studies, OPTH is already supplying commercial product to authorized clinics in Australia. 5. Licensed Platform: OPTH operates two pharmaceutical-grade facilities and holds a Health Canada DEL, GMP certification, a Dealer's Licence, and a Class A Precursor Licence. 6. Growing Market: OPTH operates within a Ps-ych-ede-lic therapeutics market that is forecast to expand from approximately $3.41B in 2026 to approximately $11.03B over the next decade. 7. Production Capacity: Current infrastructure allows OPTH to manufacture approximately 1 Mln M-D-M-A capsules and 1 Mln Psi-locy-bin capsules annually, while management has indicated utilization remains well below installed capacity. Get (OPTH) On The Radar While It’s Still Early…
When we step back and look at the bigger picture, it's easy to see why OPTH has landed on our radar. This is a company that only recently joined the Nasdaq, operates with a public float of fewer than 2.5M shares, and has already attracted new analyst coverage. At the same time, OPTH is supplying commercial product into Australia's regulated prescription market while many companies in the sector remain focused on clinical development. What also stands out is the infrastructure already in place. With two pharmaceutical-grade facilities, multiple Health Canada licenses, and annual production capacity of approximately 1 Mln M-D-M-A capsules and 1 Mln Psi-locy-bin capsules, OPTH has built a platform designed to support future demand as the market continues to evolve. Add in a Ps-ych-ede-lic therapeutics market projected to grow from approximately $3.41B to approximately $11.03B over the coming decade, and it's not hard to understand why more people are beginning to take notice. Whether your focus is emerging healthcare companies, newly listed Nasdaq names, commercial-stage businesses, or companies operating in rapidly expanding markets, OPTH is one to watch Monday. We have all eyes on OPTH this morning. Take a look at OPTH while it’s still early. Sincerely, Jeff Ackerman
Managing Editor
Stock News Trends |
No comments:
Post a Comment